Section 03

New Analysis Since April 2025

After delivering its comprehensive report and action plan to Congress in April 2025, the Commission continued to assess the biotechnology landscape and provide updated analysis in three areas to foster ongoing discussion in Congress and among U.S. biotechnology stakeholders.

This new analyses on The Future of Science, The Future of U.S.-China Biotechnology Competition, and The Future of Biotechnology Regulation represent observations from the NSCEB, drawn from extensive stakeholder consultations, that may support future policy recommendations.

Staff at the NSCEB authored the following discussion papers with input from NSCEB Commissioners. The content and recommendations of these papers do not necessarily represent positions officially adopted by the NSCEB.

The Future of Science

The NSCEB found clear warning signs that the United States is losing its innovation edge, not only in biotechnology but in science broadly. This discussion paper identifies ways to make the federal government a better partner to industry, philanthropy, and academic institutions to maximize impact and deliver breakthroughs for all Americans.

This discussion paper explores three main topics:

Making the federal government a better partner in science and technology;
Enabling autonomous scientific discovery; and
Unlocking science across America.

Read The Future of Science online or in Appendix A.

The Future of U.S.-China Biotechnology Competition

In this discussion paper, the NSCEB assessed that unless the United States takes swift policy action, the CCP’s whole-of-government approach to biotechnology will further undercut the U.S. industry, sending jobs, research and discovery, and opportunities for industry growth to China.

Read The Future of U.S.-China Biotechnology Competition online or in Appendix A.

The Future of Biotechnology Regulation

The NSCEB launched new regulatory analysis, including 83 policy options to modernize and accelerate U.S. regulatory review of biotechnology products across the federal government.

These papers build on the Commission’s April 2025 report to Congress and include 30 government-wide policy options and 53 in-depth policy options across four major product areas—medical products, plants, microorganisms, and animals—to unleash American innovation and support economic and national security.

Read The Future of Biotechnology Regulation online or in Appendix A.